A share price of Tonix Pharmaceuticals Holding Corp [TNXP] is currently trading at $19.5, down -2.55%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TNXP shares have lost -13.29% over the last week, with a monthly amount drifted -28.10%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, ROTH Capital upgraded its rating to Buy on April 18, 2019, and kept the price target unchanged to $4. On August 18, 2017, upgrade upgraded it’s rating to Buy but maintained its price target of $6 on the stock. ROTH Capital downgraded its rating to a Neutral. Oppenheimer reiterated its recommendation of a Outperform and reduced its price target to $10 on February 17, 2016. In a note dated June 12, 2015, Oppenheimer initiated an Outperform rating and provided a target price of $18 on this stock.
Tonix Pharmaceuticals Holding Corp experienced fluctuations in its stock price throughout the past year between $6.76 and $130.00. Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] shares were valued at $19.5 at the most recent close of the market.
Analyzing the TNXP fundamentals
Trailing Twelve Months sales for Tonix Pharmaceuticals Holding Corp [NASDAQ:TNXP] were 9.83M which represents -9.51% decline. Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -8.38%, Pretax Profit Margin comes in at -8.28%, and Net Profit Margin reading is -5.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Tonix Pharmaceuticals Holding Corp [NASDAQ:TNXP] is 7.53. Also, the Quick Ratio is 7.22, while the Cash Ratio stands at 6.58. Considering the valuation of this stock, the price to sales ratio is 17.39, the price to book ratio is 0.88.
Transactions by insiders
Recent insider trading involved Taylor Carolyn E., Director, that happened on Aug 21 ’25 when 418.0 shares were purchased. Director, Treco James completed a deal on Aug 20 ’25 to buy 250.0 shares. Meanwhile, Chief Executive Officer LEDERMAN SETH bought 4000.0 shares on May 15 ’25.
